The present invention relates to recombinant fragments of C. difficile TcdA and TcdB that may be used in the development of vaccines against C. difficile associated disease. More particularly it relates to combinations comprising a ToxB GT antigen and a TcdA antigen or a ToxA GT antigen and a TcdB antigen.